CervoMed (CRVO)
NASDAQ:CRVO
Want to see CRVO full AI Analyst Report?
CRVO Stock Chart & Stats
$3.98
-$0.11(-4.76%)
At close: 4:00 PM EST
$3.98
-$0.11(-4.76%)
Day’s Range― - ―
52-Week Range$3.51 - $13.13
Previous CloseN/A
Volume72.82K
Average Volume (3M)112.80K
Market Cap
$34.26M
Enterprise Value$26.30M
Total Cash (Recent Filing)$20.86M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
May 19, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.97
Shares Outstanding9,258,719
10 Day Avg. Volume143,994
30 Day Avg. Volume112,798
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)17.83
P/FCF Ratio-3.05
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue81.53
Enterprise Value/Gross Profit81.53
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$20.80Price Target Upside422.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.35
Revenue Forecast (FY)$425.00K
Bulls Say, Bears Say
Bulls Say
Biomarker-driven Patient SelectionIdentification of a plasma biomarker to exclude patients with Alzheimer’s co-pathology allows enrichment of the pivotal trial population and increases the chance of demonstrating meaningful cognitive benefit.
Manufacturing Stability And Intellectual PropertyA stable crystal form and single-step crystallization enable scalable manufacturing, improve drug stability and may support novel patent claims that could extend exclusivity.
Regulatory And Trial DesignRegulatory alignment with the FDA on primary endpoint, patient selection, trial duration and size enables a single global randomized pivotal trial toward approval and reduces development uncertainty.
Bears Say
Cash Burn And Operating LossesReported widening net losses and limited available cash highlight ongoing cash burn that may necessitate further fundraising to sustain development activities.
Execution Risk From Funding ShortfallLimited cash relative to projected operating needs raises the risk of delays or incomplete execution of the Phase 3 program if additional funding is not obtained.
Financing Dependency For Phase 3 StartAdvancement into the pivotal trial depends on securing additional financing, creating a risk that the Phase 3 program cannot commence without new capital.
CervoMed News
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $3.51 and its highest was $13.13 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is $34.26M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is May 19, 2026 which is in 12 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on Mar 17, 2026. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.866 by -$0.014.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.79.
How many shares outstanding does CervoMed have?
CervoMed has 9,258,719 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.866. Following the earnings report the stock price went up 5.104%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in CRVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CervoMed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.80 (422.61% Upside)
$20.80 (422.61% Upside)
Hedge Fund Trend
Decreased
By 74.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 16.1%
Last 30 Days ▲ 16.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.60%
12-Months-Change
Fundamentals
Return on Equity
-96.04%
Trailing 12-Months
Asset Growth
-46.15%
Trailing 12-Months
Company Description
CervoMed
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
CRVO Stock 12 Month Forecast
Average Price Target
$20.80
▲(422.61% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
44.05% Insiders
4.16% Mutual Funds
0.72% Other Institutional Investors
47.38% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---